|
Published by: SMI Publishing, Ltd
Published: Jun. 12, 2006
Table of Contents
- Day 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Professor Chas Bountra, Vice President & Head, Biology, GlaxoSmithKline.
- 9.10 ASSESSING THE PAIN THERAPEUTICS MARKET
- What are the current trends in the pain therapeutics market?
- How has the market changed over the past few years?
- Current and future approaches to the management of pain
- Tools and methods used in the treatment of pain
- Success and failures
- Recent and future patent expirations for key drugs
- Areas of pain management requiring further investment
- New models for assessing pain - examples of how to implement them
- Dr Mitchell Brin, Senior Vice President, Development Therapeutic Area Head, Botox & Neurology, Allergan.
- Dr Klaus Dembowsky, Vice President, Drug Discovery, Ingenium Pharmaceuticals.
- 9.50 REGULATORY ISSUES
- Special regulations for narcotic and pain drugs: consequences for use, distribution and development
- The potential misuse of narcotic drugs and how regulations handle this
- The effect of regulatory reviews on markets for pain products
- Pain relief as a legal right
- How has the William Hurwitz case affected pain therapeutics?
- WHO narcotic drug policies: How do regulations differ between selected countries?
- Effects of regulations for narcotic drugs on the development phase of new products
- Actual guidelines for the development of pain drugs
- Mr Horst Kastrup, Head, Worldwide Drug Regulatory Affairs, Viatris G M B H & Co K G.
- 10.30 Morning Coffee
- 10.50 ABUSE AND ADDICTION TO PRESCRIPTION OPIOID MEDICATION
- Concerns and strategies
- Abuse of prescription opioids has increased markedly in the United States
- The relationship of pain to abuse of and addiction to opioids is complex
- The need for effective but less abusable agents is acute
- Information is needed on the risk factors predicting problematic use of opioids
- Dr Wilson Compton, Director, Division of Epidemiology, Services & Prevention Research, National Institute On Drug Abuse (N I H).
- 11.30 IMAGING PAIN
- Providing an insight into the diagnosis and treatment of pain conditions
- Why image the brain during pain?
- Some neuropathic pain states produce reduced thalamic activity - how can this be monitored?
- Functional brain imaging in the comparison of neural activation patterns related to cutaneous, musculoskeletal, visceral and neuropathic pain
- Some neuropathic pain states produce reduced thalamic activity, whereas allodynia in central nervous system pain leads to activation of cortical areas - how can these be distinguished by imaging?
- At the present time functional pain imaging alone cannot be used to diagnose pain conditions or determine the effectiveness of analgesic treatments - will this ever be possible?
- The future of imaging for the treatment of pain
- Prof Irene Tracey, Director of FMRIB Centre & Pain Imaging Neuroscience Group, Oxford University.
- 12.10 POST SURGICAL PAIN
- Treatment and management
- The unmet needs from the vantage points of the:
- Healthcare system
- Surgeon
- Patient
- What are we learning from animal models?
- Current treatment approaches
- Emerging approaches and technologies
- Dr Uri Herzberg, Prinicpal Scientist, Johnson & Johnson.
- 12.50 Networking Lunch
- 2.20 ANIMAL MODELS
- How effective are animal models in the study of pain therapeutics?
- Utility of current animal models
- How to make animal disease relevant pain models
- Difficulties in assessing pain in animals
- How effective are current animal models?
- How can animal pain models be improved?
- Animal models in development
- Dr Kathryn Rogers, Director, Neuroscience Research, Wyeth.
- 3.00 HUMAN PAIN MODELS AND HOW TO MAXIMISE THEIR VALUE
- How can human pain models help improve the success rate in analgesic development?
- What are the benefits of using a human pain model rather than an animal model?
- What can be learned from clinical trials? How to avoid and overcome problems
- How to increase the success of Phase II clinical trials
- Target validation and novel pain targets in human chronic states
- What is the future for this way of testing pain therapeutics?
- Dr Boris Chizh, Director, Exploratory Pain Medicine, GlaxoSmithKline.
- 3.10 Afternoon Tea
- 4.00 TRANSLATIONAL PHARMACOLOGY IN PAIN
- Linking research and development
- Why is translational pharmacology required?
- The importance of acknowledging translational pharmacology and its uses in developing pain therapeutics
- How to simulate long-term drug-patient dynamic interactions
- The movement from animal and human studies to treatment and therapeutics
- Professor Chas Bountra, Vice President & Head, Biology, GlaxoSmithKline.
- 4.40 LOW MOLECULAR WEIGHT NGF ANTAGONISTS FOR THE TREATMENT OF PAIN
- Overview of NGF’s role in peripheral sensitization and pain
- Identification of LMW compounds that inhibit NGF activity
- In vitro profiling of lead compound series as NGF antagonists
- In vivo efficacy in animal models of acute and chronic pain
- Therapeutic potential and implications for the treatment of neuropathic pain
- Mr Kazimierz Babinski, Vice President, Drug Development, PainCeptor Pharma Corporation.
- 5.20 Chairman’s Closing Remarks and Close of Day One
- Day 2
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Wilson Compton, Director, Division of Epidemiology, Services & Prevention Research, National Institute On Drug Abuse (N I H).
- 9.10 MOLECULAR APPROACHES TO PAIN THERAPEUTICS
- Shortcomings of current therapeutics
- Review of druggable mechanisms
- Current work on these mechanisms
- Prospects for future analgesics
- Dr Alf Claesson, Principal Scientist, AstraZeneca R&D.
- 9.50 THE USE OF TRANSGENIC MICE AS A STRATEGY FOR THE DISCOVERY OF NEW PAIN TARGETS
- How do we find novel drug targets?
- Why do we need novel drug targets?
- A strategy for rapid and efficient production of transgenic mice
- The importance of thorough phenotype analysis
- The validation of potential new pain targets
- What is the future for this type of approach?
- Dr Malcolm Sheardown, Head, CNS Therapy Area, Paradigm Therapeutics.
- 10.30 Morning Coffee
- 11.00 THE THERAPEUTICS POTENTIAL OF CB2 AGONISTS IN TREATING CHRONIC PAIN STATES
- A role for CB2 receptors in chronic inflammatory and neuropathic pain states
- Proof-of-concept studies with a prototypic agonist
- On target efficacy and off target side effects
- Involvement of the opioidergic system
- Dr Garth Whiteside, Principal Research Scientist I, Wyeth Research.
- 11.40 TRPV1 AGONIST-BASED APPROACHES TO THE MANAGEMENT OF CHRONIC PAIN SYNDROMES
- The use of chemical mediators such as capsaicin
- Exposure to TRPV1 agonists can defunctionalise nociceptive nerve fibres for extended periods
- Defunctionalisation of nociceptive nerves can be restricted to target tissues
- TRPV1 agonists such as capsaicin are highly selective and have low toxicological potential
- Data from clinical trials suggests efficacy can be achieved without significant adverse events
- Dr Keith Bley, Senior Vice President, Nonclinical R & D, Neurogesx Inc.
- 12.30 IN SEARCH OF NOVEL TRPV1 ANTAGONISTS FOR PAIN MANAGEMENT
- TRPV1 receptor activation and pain signalling
- TRPV1 receptor antagonist hits through screening
- In vitro proof on concept - potent, selective and multimodal blockage of TRPV1 receptor activation by selected hits
- Separation of chiral isomers
- Efficacy profile of chiral isomers in various animal models for pain and safety pharmacology
- Dr Neelima Khairatkar-Joshi, General Manager, Glenmark Research Centre.
- 12.40 Networking Lunch
- 1.50 VANILLOID RECEPTOR ANTAGONISTS FOR PAIN
- From high-throughput screening hits to potent and selective TRPV1 antagonists
- TRPV1 antagonists block channel activation by vanilloids, heat and acid
- TRPV1 antagonists relieve pathophisiological pain in animal models
- Effect of chirality on in vitro and in vivo pharmacology of TRPV1 antagonists
- Utilisation of variety of approaches for installation of a chiral centre in TRPV1 antagonists
- Dr Arthur Gomtsyan, Associate Research Fellow, Abbott Laboratories.
- 2.30 CHEMOKINES AND PAIN
- Overview of chemokines and the receptors implicated in pain responses
- Role of inflammatory responses in the development of neuropathic pain
- Role of neuron-microglial communications in neuropathic pain establishment and maintenance
- Cross-talk between chemokine and other GPCR’s
- Dr Catherine Abbadie, Research Fellow, Merck.
- 3.10 Afternoon Tea
- 3.40 VOLTAGE GATED SODIUM CHANNEL INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN
- Application of multivalent ligand design
- Voltage-gated Na+ channels (VGSC) and pain
- Multivalent ligand design
- Na+ channels and application of multivalent ligand design
- Lidocaine dimers - in vitro VGSC profile
- Evidence for a multivalent interaction at VGSCs
- Dr Jan Smith, Director, Theravance.
- 4.20 THE IMPACT OF TRIPTANS ON MIGRAINE RESEARCH
- How have triptans unlocked migraine research?
- How studying triptan pharmacological mechanisms has led to mechanistically related targets
- Prophylaxis - a neglected research area
- The impact of migraine genetics on drug discovery
- The prospective of personalised migraine therapies
- Dr Jenny Longmore, Freelance Consultant, NeuroKnowledge.
- 5.00 Chairman’s Closing Remarks and Close of Day One
AbstractFollowing a series of well received conferences, SMi are delighted to announce their 7th annual event on Pain Therapeutics. In recent years the pain therapeutics market has been growing extensively with the overall value now reaching over $23 billion.
This conference will address key issues surrounding the market, such as the extensive regulatory concerns, abuse and addiction to prescription opioid medication and compare and contrast the use of human and animal pain models and how to best maximise their use.
Industry experts, from key companies including AstraZeneca, Wyeth, Abbott and Merck, will discuss drug classes such as the breakthrough of TRP-V1, CB2 and chemokines. Consideration will also be given to translational pharmacology in pain, how it affects the market and why it is vital to link research and development. Network with an international audience and leading speakers as they discuss the unmet needs and clinical advances in drugs used to combat pain.
A must attend event for those working in the highly competitive field of pain therapeutics!
Hear contributions from leading industry experts, including:
- Prof Chas Bountra, Vice President & Head of Biology, GlaxoSmithKline
- Dr Wilson Compton, Director, Division of Epidemiology, Services & Prevention Research, National Institute on Drug Abuse, National Institutes of Health (NIH)
- Dr Boris Chizh, Director, Exploratory Pain Medicine, GlaxoSmithKline
- Dr Kathryn Rogers, Director, Neuroscience Research, Wyeth Research
- Prof Irene Tracey, Director, FMRIB Centre & Pain Imaging Neuroscience Group, Oxford University
- Dr Catherine Abbadie, Research Fellow, Merck
- Dr Arthur Gomtsyan, Associate Research Fellow, Abbott
- Dr Uri Herzberg, Principal Scientist, Johnson & Johnson
- Dr Alf Claesson, Principal Scientist, AstraZeneca
- Dr Garth Whiteside, Principal Research Scientist I, Wyeth Research
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
